Mina Sooch - 28 Jan 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Role
President and CEO, Director
Signature
/s/ Jeffrey Kuras, by Power of Attorney
Issuer symbol
IRD
Transactions as of
28 Jan 2022
Net transactions value
$0
Form type
4
Filing time
01 Feb 2022, 15:26:43 UTC
Next filing
23 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUP Employee Stock Option (right to buy) Award $0 +200,000 $0.000000 200,000 28 Jan 2022 Common Stock 200,000 $2.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest with respect to 50,000 shares on January 28, 2023, and then with respect to 4,166 shares on the last day of each month from February 2023 through December 2025 and with respect to 4,190 shares at the end of January 2026.